Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease: interim results from the first clinical gene therapy trial

### Emily de los Reyes,<sup>1</sup> Kathrin Meyer,<sup>2</sup> Lenora Lehwald,<sup>1</sup> Charles Albright,<sup>1</sup> David L. Rogers,<sup>1</sup> Jeff Castelli,<sup>3</sup> Hai Jiang,<sup>3</sup> Allen Reha,<sup>3</sup> Jay A. Barth<sup>3</sup>

<sup>1</sup>Nationwide Children's Hospital, Columbus, OH, USA, <sup>2</sup>Nationwide Children's Hospital and Department of Pediatrics, Ohio State University, Columbus, OH, USA; <sup>3</sup>Amicus Therapeutics, Inc., Cranbury, NJ, USA


### Disclosures

- Dr. Emily de los Reyes received grants and consulting fees from Amicus and Biomarin
- This study was funded by Amicus Therapeutics, Inc.
- This presentation shares information about an investigational drug, which has not yet been approved by the FDA

# **Background and Objectives**

- Variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6), or CLN6 Batten disease, is a fatal neurodegenerative disorder for which there is no treatment<sup>1,2</sup>
- Affected children experience language delay, motor regression, intractable epilepsy, and vision loss, leading to early death in childhood<sup>1,2</sup>
- The objectives of the study are to evaluate safety and efficacy of a single intrathecal injection of AT-GTX-501, a non-replicating, recombinant, self-complementary AAV9 vector containing the human CLN6 gene, into the lumbar spinal cord for the treatment of CLN6 Batten disease

### **Methods**



### Hamburg Motor & Language (HML) Scale

Score	Motor Function	Language Function	
3	Normal	Normal (individual best performance)	
2	Frequent falls, obvious clumsiness	Recognizably abnormal	
1	No unaided walking or crawling only	Hardly understandable	
0	Immobile, mostly bedridden	Unintelligible or no language	

Q3=every 3; vg=viral genomes. Wyrwich KW et al. *J Inborn Error Metab Screening*. 2018;6:1-7.

# **Results – Primary Efficacy Analysis**


#### Rate of Decline in the HML Aggregate Score

Parameter	Statistics	12 months		24 months	
		AT-GTX-501-treated Subjects n=12 <sup>a</sup>	Natural History Subjects n=16 <sup>b</sup>	AT-GTX-501-treated Subjects n=8°	Natural History Subjects n=16 <sup>b</sup>
Rate of decline*	Mean ± SD	$0.4 \pm 0.82$	$1.2 \pm 0.40$	$0.6 \pm 0.91$	$2.4 \pm 0.79$
	Range	-1.3, 2.0	0.8, 2.0	-1.0, 2.0	1.5, 4.0
Difference between groups	Mean ± SE	-0.8 (0.26)	-	-1.8 (0.36)	-
	95% CI of Mean	(-1.4, -0.3)	-	(-2.6, -1.1)	-
	p-value	<0.01	-	<0.0001	_

\*Positive number indicates decline; negative number indicates improvement.

CI=confidence interval; SD=standard deviation; SE=standard error.

<sup>a</sup>The efficacy analysis included all patients with 12-month HML data (12 of 13 treated patients in the study). <sup>b</sup>12- and 24-month HML data are available for 16 of 17 patients in the natural history cohort derived from a retrospective CLN6 natural history study conducted by Emily de los Reyes, MD (ClinicalTrials.gov Identifier: NCT03285425). <sup>c</sup>The efficacy analysis included all patients with 24-month HML data (8 of 13 treated patients in the study). Data cutoff March 13, 2020.



M+L, motor and language. NH, natural history.

<sup>a</sup>The efficacy analysis included all patients with 24-month HML data (8 of 13 treated patients in the study). <sup>b</sup>24-month HML data are available for 16 of 17 patients in the natural history cohort derived from a retrospective CLN6 natural history study conducted by Emily de los Reyes, MD (ClinicalTrials.gov Identifier: NCT03285425). Data cutoff March 13, 2020.

# Conclusions

- Interim safety data (n=13) show that AT-GTX-501 was generally well tolerated
- 11 Grade 3 (severe) serious adverse events reported in 5 patients and 4 were considered possibly related to treatment: vomiting (2), fever (1); upper abdominal pain (1); patients recovered in all 4 cases
- No pattern of adverse events related to AAV9 or *CLN6* immunogenicity
- Interim efficacy data on AT-GTX-501 appear to demonstrate a statistically significant and meaningful treatment effect in slowing disease progression of vLINCL6 at 24 months
  - Mean rate of decline was 0.4 vs 1.2 points over 12 months in treated subjects (n=12) vs subjects from the natural history cohort (n=16) (p-value<0.01)</li>
  - Mean rate of decline was 0.6 vs 2.4 points over 24 months in treated subjects (n=8) vs subjects from the natural history cohort (n=16) (p-value<0.0001)</li>